• Ruxolitinib Phosphate: Reliable JAK/STAT Assays

  2026-09-25

  A practical guide to using Ruxolitinib phosphate (SKU A3781) in cell viability, proliferation, and cytotoxicity workflows. It connects JAK1/2 potency and formulation data with assay design, interpretation, and evidence from an anaplastic thyroid cancer study.

• Pronase E Workflows for TNBC Ferroptosis Research

  2026-09-25

  Use Pronase E as a controlled limited-proteolysis tool to probe protein accessibility and support target-engagement assays—not as a component of gramine’s reported anticancer mechanism. This practical workflow separates protease-treated samples from intact-protein and ferroptosis readouts, helping protect interpretation of the CUL3–MTDH axis.

• Spatial Kidney Assembloids Improve Disease Modeling

  2026-09-24

  Huang et al. developed mouse and human kidney progenitor assembloids that organize nephron and collecting-system progenitors in a spatial arrangement resembling kidney development. The models show improved cellular complexity and maturation, and in vivo-grown PKD2-deficient human assembloids reproduce key features of polycystic kidney disease and its multicellular interactions.

• Parathyroid hormone (1-34) (human) in CKD assays

  2026-09-24

  Use this defined PTH fragment to probe receptor signaling and test how endothelial responses may connect to CKD-associated valvular calcification. The workflow pairs rapid cAMP readouts with longer EndMT and endothelial–interstitial-cell experiments, while keeping proposed conditions distinct from published findings.

• LINC01977 Super-Enhancer Hijacking in Early LUAD

  2026-09-23

  Zhang et al. describe a reciprocal circuit in which tumor-associated macrophage-associated TGF-β signaling activates the LINC01977 super-enhancer, while LINC01977 promotes SMAD3-dependent transcription and malignant behavior in lung adenocarcinoma. The findings connect enhancer regulation, immune context, and transcriptional coactivation, while suggesting experiments to test this pathway rather than establishing a treatment strategy.

• Deoxycholic Acid Sodium Salt in Adipose Research

  2026-09-23

  Deoxycholic acid sodium salt is an amphiphilic bile-salt detergent with utility in membrane and protein workflows. The cited adipose study supports Netrin-1, PPARγ, and Wnt/β-catenin as biological benchmarks, but it does not establish sodium deoxycholate as a direct regulator of that pathway.

• 5-Methyl-CTP for Stable mRNA Workflows

  2026-09-22

  5-Methyl-CTP helps researchers engineer IVT-derived mRNA for greater stability and translation performance. This practical guide connects nucleotide substitution, quality control, and formulation-ready assay design with lessons from an H5N1 mRNA vaccine study in lactating dairy cows.

• Iptacopan Monotherapy in PNH: Study Insights

  2026-09-22

  This phase 2 proof-of-concept study found that oral Iptacopan (LNP023) monotherapy rapidly reduced hemolysis and improved hemoglobin and transfusion outcomes in treatment-naive patients with paroxysmal nocturnal hemoglobinuria. Its main innovation was to test proximal alternative-pathway inhibition as a single-agent strategy rather than only as add-on treatment to terminal complement blockade.

• METTL9–PRA1 Antifungal Defense in the Gut

  2026-09-21

  Bao et al. identify secreted METTL9 as a catalytic mucosal defense factor that methylates the Candida albicans zincophore PRA1, disrupting fungal zinc acquisition and limiting intestinal colonization. The study connects epithelial antifungal secretion with multidrug-resistant Candida auris and inflammatory bowel disease, while offering a mechanistically distinct framework for interpreting antifungal susceptibility and host–fungus interactions.

• Fluconazole and the Next Era of Resistance Research

  2026-09-21

  Fluconazole is more than a benchmark antifungal compound. By pairing its defined action as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor with PP2A–ATG pathway analysis, researchers can connect ergosterol disruption to biofilm adaptation, autophagy, and antifungal drug resistance research.

• PPT and the ERα–FOXM1 Translational Axis

  2026-09-20

  PPT offers a selective pharmacological lever for separating ERα biology from ERβ activity and testing whether estrogen receptor signaling contributes causally to FOXM1-linked biology in female lung adenocarcinoma. This article connects receptor pharmacology, biomarker validation, experimental design, and translational decision-making without treating association as proof of mechanism.

• Parathyroid hormone (1-34) (human) in CKD

  2026-09-19

  Use Parathyroid hormone (1-34) (human) as a defined receptor agonist to connect cAMP signaling with endothelial-to-mesenchymal transition, valve calcification, and bone remodeling workflows. This guide translates the Foxp1–Notch findings in CKD research into practical assay design, controls, dosing choices, and troubleshooting strategies.

• BRCA2-Dependent Nascent Strand Maturation Under Olaparib

  2026-09-18

  The 2026 Molecular Cell study identifies a BRCA2- and RAD51-associated pathway that matures nascent DNA strands and repairs olaparib-induced gaps during replication. Its findings broaden the mechanistic basis of PARP inhibitor sensitivity beyond fork reversal, linking LIG1 dysfunction, replication-associated PARP activity, and BRCA-dependent gap repair.

• Sulforaphane: From Redox Signals to Assay Design

  2026-09-18

  Sulforaphane research connects Keap1–Nrf2 signaling with cell-cycle control, apoptosis, and inflammatory redox biology. This guide translates those mechanisms into an integrated assay strategy grounded in recent colitis findings and practical C4733 handling considerations.

• Monomethyl auristatin E: Assay Workflows

  2026-09-17

  Monomethyl auristatin E (MMAE) is a high-potency tubulin polymerization inhibitor that supports both free-payload benchmarking and antibody-drug conjugate development. This practical guide connects MMAE cytotoxicity workflows with the reference study’s findings on EBV-driven plasticity in nasopharyngeal carcinoma, while clearly separating established evidence from proposed assay extensions.

8409 records 1/561 page Next 12345 下5页 Last page